Tag:

Debiopharm

Latest Headlines

Latest Headlines

Evotec lands two more deals to share risks and rewards of R&D

Germany's Evotec subverts the traditional CRO model by cozying up to its development partners with risk-splitting deals, and the company's approach to R&D has attracted Debiopharm and Convergence Pharmaceuticals with programs in cancer and chronic pain.

Debiopharm invests $6M into Immunexpress for sepsis test development

Debiopharm, the Swiss diagnostics and drug conglomerate, committed $6 million in new financing to Immunexpress, a startup focused on developing a late-stage sepsis test.

Debiopharm commits $6M to a sepsis test developer

Debiopharm, the Swiss diagnostics and drug conglomerate, committed $6 million in new financing to a startup focused on developing a late-stage sepsis test.

CRO Atheris hooks up with Debiopharm for cancer R&D

Swiss CRO Atheris Laboratories has signed a deal with Debiopharm to help develop a peptide cancer drug, optimizing leads for an innovative venom-derived treatment.

Indian CRO TCG teams with Debiopharm for antibiotics

India's TCG Lifesciences has signed up to handle early phase work for Debiopharm's drug-resistant bacteria program, helping the Swiss drug developer as it chases a share of the antibiotics market.

Cenix to collaborate with Debiopharm on predictive biomarkers

The preclinical CRO Cenix BioScience has struck a deal to work with Germany's Debiopharm, putting its experts to work finding predictive biomarkers that can be used to advance the biotech's cancer drug candidates.

CRO Cenix signs on with Debiopharm for cancer R&D

German CRO Cenix BioScience has agreed to handle preclinical work for Debiopharm's oncology pipeline, using its high-content assays to identify biomarkers.

Indian CMO Shasun inks Alzheimer's deal with Debiopharm

Swiss drugmaker Debiopharma has teamed up with India's Shasun Pharmaceuticals, striking a deal with the CMO to manufacture Huperzine-A, a drug designed to improve cognitive performance in patients with Alzheimer's disease.

Yale signs up for another drug discovery deal

Debiopharm has signed on as the latest drug developer to attend Yale laboratories for some help with early-stage research work. Yale's "leadership in marrying chemistry and biology to identify and

Marina, Debiopharm partner on RNAi-based bladder cancer work

Switzerland's Debiopharm will pay up to $25 million in R&D milestones to partner with Marina Biotech on the company's preclinical program for non-muscle invasive bladder cancer. Marina can look